Valor prognóstico da expressão por imuno-histoquímica do c-erb-2. Em doentes sob terapêutica adjuvante com Tamoxifeno por carcinoma primário da mama.

Andreia Antunes; Teresa Silva; Isabel Godinho; Natália Amaral; Calos Oliveira

doi:10.20344/amp.1100

Prognostic value of c-erb-2 immunohistochemistry expression in patients with primary breast cancer and adjuvant treatment with tamoxifen.

Authors

Andreia Antunes Serviços de Ginecologia e de Anatomia Patológica, Hospitais da Universidade de Coimbra, Coimbra.
Teresa Silva
Isabel Godinho
Natália Amaral
Calos Oliveira

DOI:

https://doi.org/10.20344/amp.1100

Abstract

The c-erb2 proto-oncogene is a member of the epidermal growth factor receptor family and has been associated with a more aggressive breast tumour biology and resistance to some types of treatments.To evaluate the prognostic value of c-erb-2 receptor, from primary breast cancer on tamoxifen therapy.We examined 66 paraffin-embedded sections from primary breast cancers. Patients were treated with surgery plus adjuvant treatment with tamoxifen; 58% had also received chemotherapy and/or radiotherapy. Membrane staining for c-erb-2 was evaluated by immunohistochemistry and overall survival and relapse-free survival were compared between positives and negatives for c-erb-2.43,9% of tumours over expressed c-erb-2 receptor, but this was not associated with a worse prognosis on overall survival either on relapse free-survival, with a p value of 0,15 and 0,2 respectively.There is not any advantage to determine c-erb-2 as a prognostic factor on overall survival either on relapse free-survival. Attending the homogenous characteristics between both groups with any statistical differences according age.

Downloads

Download data is not yet available.

Downloads

PDF (Português)

How to Cite

Antunes A, Silva T, Godinho I, Amaral N, Oliveira C. Prognostic value of c-erb-2 immunohistochemistry expression in patients with primary breast cancer and adjuvant treatment with tamoxifen. Acta Med Port [Internet]. 2004 Aug. 31 [cited 2024 Dec. 25];17(4):271-6. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/1100

Download Citation

Issue

Vol. 17 No. 4 (2004): July-August

Section

Arquivo Histórico

License

All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.

It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.

Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.

After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.